QbD based Eudragit coated Meclizine HCl immediate and extended release multiparticulates: formulation, characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method.

ABSTRACT: This study is based on the QbD development of extended-release (ER) extruded-spheronized pellets of Meclizine HCl and its comparative pharmacokinetic evaluation with immediate-release (IR) pellets. HPLC-fluorescence method was developed and validated for plasma drug analysis. IR drug cores were prepared from lactose, MCC, and PVP using water as granulating fluid. Three-level, three-factor CCRD was applied for modeling and optimization to study the influence of Eudragit (RL100-RS100), TEC, and talc on drug release and sphericity of coated pellets. HPLC-fluorescence method was sensitive with LLOQ 1 ng/ml and linearity between 10 and 200 ng/ml with R²?>?0.999. Pharmacokinetic parameters were obtained by non-compartmental analysis and results were statistically compared using logarithmically transformed data, where p?>?0.05 was considered as non-significant with a 90% CI limit of 0.8-1.25. The AUC_0-t and AUC_0-? of ER pellets were not significantly different with geometric mean ratio 1.0096 and 1.0093, respectively. The C_max of IR pellets (98.051 ng/ml) was higher than the ER pellets (84.052 ng/ml) and the T_max of ER pellets (5.116 h) was higher than the IR pellets (3.029 h). No significant food effect was observed on key pharmacokinetic parameters of ER pellets. Eudragit RL100 (6%) coated Meclizine HCl pellets have a potential therapeutic effect for an extended time period.

SUBMITTER: Qazi F 

PROVIDER: S-EPMC7484796 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature